Criminal drug trafficking organizations in northern Mexico are covertly controlling what substances people with opioid addiction consume, mixing fentanyl into heroin supplies without warning and introducing dangerous adulterants like xylazine that complicate recovery efforts and overdose prevention. This shift represents a fundamental challenge to public health strategies focused on addiction treatment, as users lose the ability to make informed choices about their own drug use. How Are Criminal Groups Controlling Local Drug Markets? Over the past two decades, Mexico's major drug trafficking organizations have fragmented into smaller, localized factions that now dominate street-level drug distribution. In border cities like Mexicali and Tijuana in Baja California, criminal groups like the Rusos, once an armed wing of the Sinaloa Cartel, have shifted their focus toward controlling local markets rather than just trafficking drugs across borders. These organizations have implemented strict systems to ensure monopoly control over supply. Doses are standardized, packaging is marked with authorization seals, and sales are tightly controlled, dictating exactly what can be sold, where, and by whom. Independent dealers who once operated freely have been pushed out or forced to comply with these new rules. One long-term heroin user in Mexicali, who has used opioids for approximately 25 years, described the transformation: "Buying drugs isn't about choice anymore, it's about whatever's available." She explained that she used to buy in bulk from trusted independent dealers and could be certain of what she was purchasing. Today, that certainty no longer exists. Why Is Fentanyl Being Mixed Into Heroin Without Users' Knowledge? The introduction of fentanyl into local drug markets was driven by two major forces. First, Mexican criminal networks supplying the US opioid market discovered that fentanyl, a synthetic opioid up to 50 times stronger than heroin, offered significant economic advantages. Unlike plant-based drugs, fentanyl can be easily mixed with other substances, trafficked in much smaller quantities, and requires far less investment to produce. Second, as criminal organizations consolidated control over local markets, they began covertly mixing fentanyl into heroin supplies about 10 years ago, introducing it without warning and without users' consent. The impact on the streets was devastating. Unaware that fentanyl had entered circulation, many users suffered overdoses and deaths that the Mexican government has yet to fully document. The drug brought new health consequences beyond overdose risk. Users reported harsher withdrawal symptoms, heightened anxiety, intense physical pain, and severe skin lesions. But users had little choice. As one long-term user stated: "I don't like fentanyl, but it's not like I can ask them to just sell me heroin. Now, you can only buy what they give you". Steps to Understanding Polydrug Contamination and Its Health Risks - Xylazine Emergence: By late 2023, community-based organizations in Mexicali and Tijuana discovered that xylazine, a veterinary sedative not approved for human use, had quietly entered the fentanyl supply. Users began overdosing more frequently and severely, and even after receiving naloxone, the opioid overdose antidote, some remained sedated for hours. - Unpredictable Supply Chains: Fentanyl producers in Sinaloa facing temporary shortages of key chemical precursors turned to xylazine and other veterinary tranquilizers like zoletil to stretch product volume and increase profits. These batches were mixed with unadulterated fentanyl shipments before reaching retail markets, making it impossible for dealers or users to know which doses contained xylazine. - Polydrug Contamination Expansion: A new concern has surfaced for treatment providers and emergency personnel across the border. Polydrug contamination, particularly involving fentanyl and stimulant drugs, is pushing overdose risks into populations beyond opioid users, expanding the public health crisis. Community-based organizations responded by urging users to bring their drug paraphernalia and packaging for testing with strips that detect xylazine, allowing them to know in advance whether their dose contained it. The wave of xylazine contamination passed quickly, underscoring just how volatile synthetic drug markets can be. By April 2024, when public health authorities finally issued an official alert, xylazine had virtually disappeared from Tijuana and Mexicali's streets. What Does This Mean for Addiction Recovery and Public Health? As international drug policy increasingly moves toward public health strategies focused on treatment and harm reduction, the experiences in northern Mexico reveal a critical gap. Criminal control over local markets, and the decisions criminal actors make about supply, can severely challenge these efforts. In the United States, the addiction crisis continues to affect millions. Nearly 28 million Americans face Alcohol Use Disorder, and while younger generations are drinking less overall, those who do drink are consuming more heavily. The pandemic saw a rise in high-intensity drinking among younger adults, and that number has remained elevated, with nearly 15 percent of adults aged 18 to 25 meeting the criteria for alcohol use disorder. Recovery programs and treatment providers are working to address these challenges through comprehensive approaches. Treatment centers like Delphi Rise offer medication-assisted therapy, counseling, and connections to community resources including housing and employment support, meeting people where they are and providing services tailored to individual needs. The situation in Mexico highlights a sobering reality: even when public health systems implement evidence-based addiction treatment and harm reduction strategies, criminal control over drug supply can undermine these efforts. Users cannot make informed decisions about their own health when they do not know what substances they are consuming. This disconnect between public health goals and criminal market dynamics represents one of the most pressing challenges in addiction recovery today.
